Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST2818 in EGFR T790M-positive NSCLC (Phase II)
CTR20180154Phase 2Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Feb 2018; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20180154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180154.